Brief: Candel Therapeutics Inc - Announces Encouraging Interim Data From CAN-3110 Trial
14/10/2025 13:17
Oct 14 (Reuters) - Candel Therapeutics Inc CADL.O: CANDEL THERAPEUTICS INC - ANNOUNCES ENCOURAGING INTERIM DATA FROM CAN-3110 TRIAL CANDEL THERAPEUTICS INC - UPDATED MEDIAN OS OF 11.8 MONTHS FOR ARM A, 12.0 MONTHS FOR ARM B Source text: ID:nGNX1vqDPC Further company coverage: CADL.O
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec